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This Month in the Journal
Failure to Confirm DUP25 by FISH in the U.K., by
Tabiner et al. (p. 535)
An unusual interstitial duplication (DUP25) on chromo-
some 15q24–q26 has previously been reported in indi-
viduals with anxiety disorders (by Grataco`s et al., inCell
106:367–379 [cited by Tabiner et al.]). DUP25 occurred
in three forms and was found in a mosaic state in 97%
of a sample of Spanish panic disorder/agoraphobia suf-
ferers and 7% of control individuals. Tabiner et al. at-
tempt to replicate this finding in case and control indi-
viduals from the United Kingdom. Using almost identical
probes to those used by Grataco`s et al., they found no
evidence of DUP25 in 16 patient and 40 control samples.
To verify their experimental procedure, three CEPH cell
lines that scored positive for DUP25 in the Grataco`s et
al. study were used as positive controls in this study,
and, again, no evidence of DUP25 was found. However,
suspensions of these cell lines were sent back to the au-
thors of the original paper for testing, and anywhere
from 15%–45% of the cells in each line were scored as
DUP25-positive by that lab. Perhaps the procedural dif-
ferences that led to these opposite findings can be de-
termined so that the existence of DUP25 can be defin-
itively confirmed or refuted.
Mitochondrial DNA Mutations and HIV Therapy, by
Martin et al. (p. 549)
The mtDNA polymerase-g is inhibited by nucleoside an-
alog reverse transcriptase inhibitors (NRTI) because, un-
like the nuclear DNA polymerases, it can’t effectively
discriminate NRTIs from endogenous nucleosides. NRTI
therapy has been associated with mtDNA depletion, and
Martin et al. decided to assess its effects on mtDNA
sequences. To do this, they collected peripheral blood
samples from HIV-infected individuals prior to and fol-
lowing several months of NRTI therapy, and they com-
pared mtDNA SSCP and sequence data between these
samples. A control group of HIV-infected individuals who
did not receive NRTI therapy was used for comparison.
Different SSCP patterns were observed between the be-
fore- and after-treatment samples in 5 of the 16 patients
receiving NRTI therapy. This difference corresponded
with an increase in the number of heteroplasmic mtDNA
populations following treatment, as well as a decrease
in the levels of mtDNA in blood. It seems, therefore,
that several months of NRTI therapy may promote the
development of mtDNA mutations in peripheral blood.
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Further work will be required before the effects of these
mutations can be determined, although preliminary ev-
idence in this study indicates that NRTI-associated lipo-
atrophy may be one.
EVC2 Mutated in EvC Syndrome, by Ruiz-Perez et al.
(p. 728)
A large percentage of individuals with Ellis-van Creveld
(EvC) syndrome, an autosomal recessive chondro-
dysplasia, do not appear to have mutations in EVC,
which is the only gene known to be responsible for this
syndrome. This includes some pedigrees with EvC who
show evidence of genetic localization to the EVC region.
Ruiz-Perez et al. collected seven such families to examine
other genes in this region and to see if they could find
a second EvC gene. The orthologue of a novel gene in
the region was recently found to be mutated in bovine
chondrodysplastic dwarfism, which has some pheno-
typic similarity to EvC, so the authors focused on this
gene. Five truncating and one missense mutation were
found, and the gene was thus dubbed “EVC2.” It is
interesting that EVC2 is arranged in a head-to-head con-
figuration with EVC and their transcription start sites
are separated by only ∼2,600 bp. Although no obvious
similarities exist between these genes, and their functions
are as yet unknown, it could be that they are regulated
in a coordinated fashion through their shared promoter
region. These findings are supported by a recent publi-
cation that also identified two potentialEVC2mutations
in an individual with EvC and that suggested a shared
promoter region between EVC and EVC2 (see Gald-
zicka et al. [2002] Mol Gen Metab 77:291–295).
L1 Evolution in Great Apes, by Mathews et al. (p.
739)
Long interspersed elements (LINEs) have been an im-
portant driving force for genomic evolution and are es-
timated to have been involved in the creation of a large
portion of the human genome. Mathews et al. investigate
this evolution through a study of L1 retrotransposons,
the youngest LINEs in mammalian genomes. Through
a PCR procedure, they generate unbiased libraries of
recent L1s in human, chimpanzee, and bonobo. Com-
parisons of the L1 clone sequences allow them to identify
species-specific L1 insertions. On the basis of the num-
bers of species-specific insertions, they calculate that L1s
have accumulated in the Pan lineages at rates 2.3–3-fold
faster than in the Homo lineage, since their divergence.
Extrapolating from their results, the chimpanzee and
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bonobo genomes may have as many as 760–1,140 full-
length L1 insertions that are absent from humans. This
type of genomic change may have played a role in the
differentiation of humans from our closest relatives.
Novel Missense Mutations in LRP5 Gene, by Van
Wesenbeeck et al. (p. 763)
The low-density lipoprotein receptor-related protein 5
(LRP5) is a Wnt coreceptor that is expressed in osteo-
blasts and is required for optimal Wnt signaling in these
cells. Inactivating mutations in LRP5 have been found
in patients with osteoporosis pseudoglioma syndrome,
a syndrome that includes very low bone mass, whereas
a putative gain of function mutation has been found in
two families with high bone density. Additional evidence
supports the role of this protein in the regulation of bone
mass in vertebrates. To examine further the range of
clinical phenotypes associated with LRP5 mutations,
Van Wesenbeeck et al. gather a cohort of individuals and
families with phenotypes associated with increased bone
density, including endosteal hyperostosis, Van Buchem
disease, autosomal dominant osteosclerosis, and auto-
somal dominant osteopetrosis type I. Missense muta-
tions of LRP5 were identified in 10 families. It appears,
therefore, that LRP5 should be suspect in a range of
conditions marked by increased bone density.
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